Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to speed up the commercialization ofSeqWell and Codexis genomics work process arrangements. Codexis, a main compound designing organization empowering the guarantee of engineered science, and SeqWell and Codexis, a designer of groundbreaking library readiness items for demanding genomics applications, plan to team up on involving Codexis’ CodeEvolver® stage innovation for catalyst enhancement with SeqWell and Codexis developing arrangement of genomics work process and library planning items.
As a feature of this partnership, Codexis drove seqWell’s $7 million Series C funding with a $5 million investment. Flow financial backers Research Corporation Technologies (RCT) and BroadOak Capital Partners likewise took an interest in the Series C supporting. This cooperation and investment empower SeqWell and Codexis to proceed with quickly propelling its commercialization of new and existing items in the quickly developing genomics and cutting edge sequencing (NGS) library prep market.
seqWell’s plexWell™ stage is a NGS library planning innovation that empowers straightforward, adaptable multiplexing of hundreds to thousands of tests without the requirement for time-and cost-consuming example arrangement or library standardization steps. Through this partnership, the innovation will be coordinated with Codexis’ CodeEvolver® stage for finding and creating novel, elite execution compounds and novel biotherapeutics, to additional development SeqWell and Codexis developing arrangement of genomics work process and library readiness items. By outfitting upgraded protein based arrangements, SeqWell and Codexis plans to change the speed and exactness of sequencing applications inside the quickly developing genomics and NGS markets.